RTALB Fair Value & Analysis
Healthcare · TR · Market cap 1.5B TRY
Fair value as of: Aug 1, 2026
From 23 valuation models · updated today
Share price −11.1% over the past month.
Price vs Fair Value (12 months)
12‑month range 3.01 TRY – 4.71 TRY · fair‑value band 2.32 TRY – 5.50 TRY · the 3.05 TRY price screens below the 3.56 TRY fair value. As of Aug 1, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
RTALB (RTALB) currently trades at 3.05 TRY, while our model-based Fair Value estimate is 3.56 TRY, implying the stock looks roughly 16.7% undervalued today. We read business quality at 48/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Trailing-twelve-month revenue stands at 254M TRY. Revenue grew 20.8% year over year. It earns a return on equity of 12.4%. Net debt stands at 109M TRY. Fundamentals as of Aug 1, 2026
Our scenario range runs from 2.32 TRY (bear case) to 5.50 TRY (bull case); at 3.05 TRY, the current price sits within that range. The share trades about 40% below its 52-week high and 1% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside, at 17%, RTALB screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 1, 2026. TTM = trailing twelve months.
Quality Score breakdown
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S. engages in the research, development, and production of microbiology and molecular biology products in Turkey.
Full company description
RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S. engages in the research, development, and production of microbiology and molecular biology products in Turkey. It offers real-time PCR kits, nucleic acid extraction kits, microbiology media, microbiology stains, and rapid tests; standards and reference materials, and membrane filters; chemicals and reactives, membrane filters, microbiology gas generators, and other consumables; and instruments and consumables. RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S. was incorporated in 1996 and is based in Kocaeli, Turkey.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
RTALB reported revenue of 240M TRY in FY2025 versus 384M TRY in FY2021, a compound −11.1%/yr. Reported net income was 881M TRY in FY2025, compounding +66.6%/yr from FY2021.
Is RTALB fairly valued? → Check now
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 1, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 449.62 MXN | -94% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.04 | R$46.95 | -10% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 167,300 KRW | 76,382 KRW | -54% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| WuXi Biologics (Cayman) Inc 2269 | HK$32.74 | HK$24.99 | -24% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
| Genmab A/S GMAB | kr 1,704 | kr 209.21 | -88% |
Compare RTALB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is RTALB overvalued or undervalued?
What is the fair value of RTALB?
What is the quality score of RTALB?
What is the revenue of RTALB?
What is the net profit margin of RTALB?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track RTALB and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.